Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barbara Rebesco

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Tumori|February 7, 2006
[Cost effectiveness analysis of two adjuvant regimens in the treatment of colorectal cancer: an interpretation of the MOSAIC Study]Barbara Rebesco, Elena Cantagalli, Maria Elvira Amalfitano
Global & Regional Health Technology Assessment|January 22, 2026
Claudio Jommi, Barbara Rebesco, Francesco Perrone, et al.
Healthcare (Basel, Switzerland)|November 27, 2021
Innovative Clinical-Organizational Model to Ensure Appropriateness and Quality in the Management of Medical Cannabis: An Italian Regional CaseEleonora Russo, Clara Cannas, Maria Susanna Rivetti, et al.
Tumori|September 2, 2016
Risk management of onco-hematological drugs: how and how fast can we improve?Mattia Altini, Marna Bernabini, Paolo Marchetti, et al.
Vaccines|June 27, 2025
Determinants of Accepting or Rejecting Influenza Vaccination-Results of a Survey Among Ligurian Pharmacy Visitors During the 2023/2024 Vaccination CampaignDaniela Amicizia, Silvia Allegretti, Federico Grammatico, et al.
The Journal of Antimicrobial Chemotherapy|July 23, 2009
Incidence of candidaemia and relationship with fluconazole use in an intensive care unitMatteo Bassetti, Filippo Ansaldi, Laura Nicolini, et al.
Plos One|May 9, 2015
Doxorubicin impairs the insulin-like growth factor-1 system and causes insulin-like growth factor-1 resistance in cardiomyocytesPatrizia Fabbi, Paolo Spallarossa, Silvano Garibaldi, et al.
Frontiers in Immunology|June 19, 2018
Targeting the Epidermal Growth Factor Receptor Can Counteract the Inhibition of Natural Killer Cell Function Exerted by Colorectal Tumor-Associated FibroblastsDelfina Costa, Roberta Venè, Roberto Benelli, et al.
American Journal of Hematology|April 17, 2016
High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patientsFabio Guolo, Paola Minetto, Marino Clavio, et al.
Journal of Clinical Medicine|October 23, 2021
Early Administration of Bamlanivimab in Combination with Etesevimab Increases the Benefits of COVID-19 Treatment: Real-World Experience from the Liguria RegionAntonio Vena, Giovanni Cenderello, Elisa Balletto, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Tumori|February 7, 2006
[Cost effectiveness analysis of two adjuvant regimens in the treatment of colorectal cancer: an interpretation of the MOSAIC Study]Barbara Rebesco, Elena Cantagalli, Maria Elvira Amalfitano
Global & Regional Health Technology Assessment|January 22, 2026
Claudio Jommi, Barbara Rebesco, Francesco Perrone, et al.
Healthcare (Basel, Switzerland)|November 27, 2021
Innovative Clinical-Organizational Model to Ensure Appropriateness and Quality in the Management of Medical Cannabis: An Italian Regional CaseEleonora Russo, Clara Cannas, Maria Susanna Rivetti, et al.
Tumori|September 2, 2016
Risk management of onco-hematological drugs: how and how fast can we improve?Mattia Altini, Marna Bernabini, Paolo Marchetti, et al.
Vaccines|June 27, 2025
Determinants of Accepting or Rejecting Influenza Vaccination-Results of a Survey Among Ligurian Pharmacy Visitors During the 2023/2024 Vaccination CampaignDaniela Amicizia, Silvia Allegretti, Federico Grammatico, et al.
The Journal of Antimicrobial Chemotherapy|July 23, 2009
Incidence of candidaemia and relationship with fluconazole use in an intensive care unitMatteo Bassetti, Filippo Ansaldi, Laura Nicolini, et al.
Plos One|May 9, 2015
Doxorubicin impairs the insulin-like growth factor-1 system and causes insulin-like growth factor-1 resistance in cardiomyocytesPatrizia Fabbi, Paolo Spallarossa, Silvano Garibaldi, et al.
Frontiers in Immunology|June 19, 2018
Targeting the Epidermal Growth Factor Receptor Can Counteract the Inhibition of Natural Killer Cell Function Exerted by Colorectal Tumor-Associated FibroblastsDelfina Costa, Roberta Venè, Roberto Benelli, et al.
American Journal of Hematology|April 17, 2016
High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patientsFabio Guolo, Paola Minetto, Marino Clavio, et al.
Journal of Clinical Medicine|October 23, 2021
Early Administration of Bamlanivimab in Combination with Etesevimab Increases the Benefits of COVID-19 Treatment: Real-World Experience from the Liguria RegionAntonio Vena, Giovanni Cenderello, Elisa Balletto, et al.
Pageof 1